Synairgen Share News (SNG)
SNG Share
SNG Share
SNG Share
SNG Share
SNG
SNG Share
SNG Level 2
SNG Live
SNG Broker
SNG Directors
SNG Financial
SNG
SNG Short
SNG
Last checked at -
Thu, 18th Apr 2019 11:52
LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June 3.
Iain Buchanan, non-executive director, will take on the chairmanship of the remuneration committee from the same date, the respiratory drug discovery company said.
Synairgen shares were trading down 3.7% at 13.00 pence each on Thursday.
IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US
Read moreTRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal
Read more
(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.
Read moreIN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ
Read moreAIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit
Read moreEARNINGS UPDATES: President Energy slims loss; Jangada turns a profit
Read moreUK earnings, trading statements calendar - next 7 days
Read moreUK shareholder meetings calendar - next 7 days
Read moreTRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling
Read more(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.
Read moreTRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss
Read moreTRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump
Read more(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.
Read moreIN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study
Read moreTRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic
Read more
Last checked at